Evidence-based Danish Guidelines for the Treatment of Malasseziarelated Skin Diseases

Acta Dermato-Venereologica

Volumn 95, Issue 1, 2015, Pages 12-19

  Hald, Marianne ^a   Arendrup, Maiken C ^b   Svejgaard, Else L ^a   Lindskov, Rune ^c   Foged, Erik K ^d   Saunte, Ditte Marie L ^e  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

^c Dermatology Clinic   (Denmark)

^d The Dermatology Clinic   (Denmark)

^e ROSKILDE HOSPITAL   (Denmark)

Author keywords

Guidelines; Malassezia; Malassezia folliculitis; Pityriasis versicolor; Seborrhoeic dermatitis

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFLAMMATORY AGENT; CALCINEURIN INHIBITOR; CORTICOSTEROID;

DERMATITIS, SEBORRHEIC; DERMATOLOGY; DRUG ADMINISTRATION; DRUG COMBINATION; EVIDENCE BASED MEDICINE; FOLLICULITIS; HUMAN; INTRADERMAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MALASSEZIA; MICROBIOLOGY; PRACTICE GUIDELINE; STANDARDS; TIME; TINEA VERSICOLOR; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; ANTIFUNGAL AGENTS; CALCINEURIN INHIBITORS; DERMATITIS, SEBORRHEIC; DERMATOLOGY; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; FOLLICULITIS; HUMANS; MALASSEZIA; TIME FACTORS; TINEA VERSICOLOR; TREATMENT OUTCOME;

EID: 84918830392     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-1825     Document Type: Article

References (82)

1. Cafarchia C, Gasser RB, Figueredo LA, Latrofa MS, Otranto D. Advances in the identification of Malassezia. Mol Cell Probes 2011; 25: 1-7.
2. Arendrup MC, Boekhout T, Akova M, Meis JF, Cornely OA, Lortholary O, et al. ESCMID/ECMM Joint clinical Guideline for the diagnosis and management of rare invasive yeast infections. Clin Microbiol Infect 2014; Suppl 3: 76-98.
3. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ 1999; 318: 593-596.
4. Lortholary O, Petrikkos G, Akova M, Arendrup MC, Arikan-Akdagli S, Bassetti M, et al. ESCMID* guideline for the diagnosis and management of candida diseases 2012: patients with HIV infection or AIDS. Clin Microbiol Infect 2012; 18: 68-77.
5. Gaitanis G, Magiatis P, Hantschke M, Bassukas ID, Velegraki A. The Malassezia genus in skin and systemic diseases. Clin Microbiol Rev 2012; 25: 106-141.
6. Gupta A, Bluhm R, Summerbell R. Pityriasis versicolor. J Eur Acad Dermatol Venereol 2002; 16: 19-33.
7. Gupta AK, Ryder JE, Nicol K, Cooper EA. Superficial fungal infections: an update on pityriasis versicolor, seborrheic dermatitis, tinea capitis, and onychomycosis. Clin Dermatol 2003; 21: 417-425.
8. Marples MJ. The incidence of certain skin diseases in western Samoa: a preliminary survey. Trans R Soci Trop Med Hyg 1950; 44: 319-332.
9. Hafez M, El-Shamy S. Genetic susceptibility in pityriasis versicolor. Dermatologica 1985; 171: 86-88.
10. Faergemann J. Management of seborrheic dermatitis and pityriasis versicolor. Am J Clin Dermatol 2000; 1: 75-80.
11. Mendez-Tovar LJ. Pathogenesis of dermatophytosis and tinea versicolor. Clin Dermatol 2010; 28: 185-189.
12. Faergemann J. Pityrosporum ovale and skin diseases. Keio J Med 1993; 42: 91-94.
13. Gupta AK, Batra R, Bluhm R, Boekhout T, Dawson TL Jr. Skin diseases associated with Malassezia species. J Am Acad Dermatol 2004; 51: 785-798.
14. Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, et al. Guidelines of care for superficial mycotic infections of the skin: Pityriasis (tinea) versicolor. Guidelines/Outcomes Committee. American Academy of Dermatology. J Am Acad Dermatol 1996; 34: 287-289.
15. Hu SW, Bigby M. Pityriasis versicolor: a systematic review of interventions. Arch Dermatol 2010; 146: 1132-1140.
16. Fredriksson T, Faergemann J. Double-blind comparison of a zinc pyrithione shampoo and its shampoo base in the treatment of tinea versicolor. Cutis 1983; 31: 436-437.
17. Hull CA, Johnson SM. A double-blind comparative study of sodium sulfacetamide lotion 10% versus selenium sulfide lotion 2.5% in the treatment of pityriasis (tinea) versicolor. Cutis 2004; 73: 425-429.
18. Hersle K. Selenium sulphide treatment of tinea versicolor. Acta Derm Venereol 1971; 51: 476-478.
19. Faergemann J, Fredriksson T. Propylene glycol in the treatment of tinea versicolor. Acta Derm Venereol 1980; 60: 92-93.
20. Montero-Gei F, Robles ME, Suchil P. Fluconazole vs. Itraconazole in the treatment of tinea versicolor. Int J Dermatol 1999; 38: 601-603.
21. Faergemann J, Gupta AK, Al Mofadi A, Abanami A, Shareaah AA, Marynissen G. Efficacy of itraconazole in the prophylactic treatment of pityriasis (tinea) versicolor. Arch Dermatol 2002; 138: 69-73.
22. Dehghan M, Akbari N, Alborzi N, Sadani S, Keshtkar AA. Single-dose oral fluconazole versus topical clotrimazole in patients with pityriasis versicolor: A double-blind randomized controlled trial. J Dermatol 2010; 37: 699-702.
23. Partap R, Kaur I, Chakrabarti A, Kumar B. Single-dose fluconazole versus itraconazole in pityriasis versicolor. Dermatology 2004; 208: 55-59.
24. [Nizoral® creme and shampoo] [Internet]. [cited 2013 Jul 29]. Available from: http://pro.medicin.dk/Medicin/ Praeparater/3743 (in Danish).
25. Gupta AK, Batra R, Bluhm R, Faergemann J. Pityriasis versicolor. Dermatol Clin 2003; 21: 413-429.
26. No authors listed. Evaluation of a new antifungal cream, ciclopirox olamine 1% in the treatment of cutaneous candidosis. Clin Ther 1985; 8: 41-48.
27. Tanenbaum L, Anderson C, Rosenberg MJ, Akers W. 1% sulconazole cream v 2% miconazole cream in the treatment of tinea versicolor. A double-blind, multicenter study. Arch Dermatol 1984; 120: 216-219.
28. Sánchez JL, Torres VM. Double-blind efficacy study of selenium sulfide in tinea versicolor. J Am Acad Dermatol 1984; 11: 235-238.
29. Yazdanpanah MJ, Azizi H, Suizi B. Comparison between fluconazole and ketoconazole effectivity in the treatment of pityriasis versicolor. Mycoses 2007; 50: 311-313.
30. Farschian M, Yaghoobi R, Samadi K. Fluconazole versus ketoconazole in the treatment of tinea versicolor. J Dermatol Treat 2002; 13: 73-76.
31. Köse O, Bülent Taştan H, Riza Gür A, Kurumlu Z. Comparison of a single 400 mg dose versus a 7-day 200 mg daily dose of itraconazole in the treatment of tinea versicolor. J Dermatolog Treat 2002; 13: 77-79.
32. Crespo Erchiga V, Delgado Florencio V. Malassezia species in skin diseases. Curr Opin Infect Dis 2002; 15: 133-142.
33. Gupta A, Bluhm R. Seborrheic dermatitis. J Eur Acad Dermatol Venereol 2004; 18: 13-26.
34. Faergemann J, Bergbrant IM, Dohsé M, Scott A Westgate G. Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry. Br J Dermatol 2001; 144: 549-556.
35. Gupta AK, Bluhm R, Cooper EA, Summerbell RC, Batra R. Seborrheic dermatitis. Dermatol Clin 2003; 2: 401-412.
36. Ruiz-Maldonado R, López-Matinez R, Pérez Chavarria EL, Rocio Castañón L, Tamayo L. Pityrosporum ovale in infantile seborrheic dermatitis. Pediatr Dermatol 1989; 6: 16-20.
37. Broberg A, Faergemann J. Infantile seborrhoeic dermatitis and Pityrosporum ovale. Br J Dermatol 1989; 120: 359-362.
38. Binder RL, Jonelis FJ. Seborrheic dermatitis in neurolepticinduced parkinsonism. Arch Dermatol 1983; 119: 473-475.
39. Naldi L, Rebora A. Seborrheic dermatitis. N Engl J Med 2009; 360: 387-396.
40. Berk T, Scheinfeld N. Seborrheic dermatitis. P T 2010; 35: 348-352.
41. Schwartz JR, Messenger AG, Tosti A, Todd G, Hordinsky M, Hay RJ, et al. A comprehensive pathophysiology of dandruff and seborrheic dermatitis - towards a more precise definition of scalp health. Acta Derm Venereol 2013; 93: 131-137.
42. Tegner E. Seborrhoeic dermatitis of the face induced by PUVA treatment. Acta Derm Venereol 1983; 63: 335-339.
43. Piérard-Franchimont C, Goffin V, Decroix J, Piérard GE. A multicenter randomized trial of ketoconazole 2%; and zinc pyrithione 1%; shampoos in severe dandruff and seborrheic dermatitis. Skin Pharmacol Appl Skin Physiol 2002; 15: 434-441.
44. Stratigos JD, Antoniou C, Katsambas A, Böhler K, Fritsch P, Schmölz A, et al. Ketoconazole 2% cream versus hydrocortisone 1% cream in the treatment of seborrheic dermatitis. A double-blind comparative study. J Am Acad Dermatol 1988; 19: 850-853.
45. Cook BA Warshaw EM. Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis: a review of pathophysiology, safety, and efficacy. Am J Clin Dermatol. 2009; 10: 103-118.
46. Firooz A, Solhpour A, Gorouhi F, Daneshpazhooh M, Balighi K, Farsinejad K, et al. Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigatorblind, clinical trial. Arch Dermatol 2006; 142: 1066-1067.
47. Rigopoulos D, Ioannides D, Kalogeromitros D, Gregoriou S, Katsambas A. Pimecrolimus cream 1% vs. betametha-sone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. Br J Dermatol 2004; 151: 1071-1075.
48. Warshaw EM, Wohlhuter RJ, Liu A, Zeller SA, Wenner RA, Bowers S, et al. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol 2007; 57: 257-264.
49. Wollina U. The role of topical calcineurin inhibitors for skin diseases other than atopic dermatitis. Am J Clin Dermatol 2007; 8: 157-173.
50. Braza TJ, DiCarlo JB, Soon SL, McCall CO. Tacrolimus 0.1% ointment for seborrhoeic dermatitis: an open-label pilot study. Br J Dermatol 2003; 148: 1242-1244.
51. Meshkinpour A, Sun J, Weinstein G. An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. J Am Acad Dermatol 2003; 49: 145-147.
52. Koc E, Arca E, Kose O, Akar A. An open, randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the treatment of seborrheic dermatitis. J Dermatol Treat 2009; 20: 4-9.
53. Peter RU, Richarz-Barthauer U. Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketokonazole shampoo: results of a multicentre, double-blind, placebo-controlled trial. Br J Dermatol 1995; 132: 441-445.
54. Faergemann J. Seborhoeic dermatitis and Pityrosporum orbiculare: treatment of seborrhoeic dermatitis of the scalp with miconazole-hydocortisone (Daktacort), miconazole and hydrocortisone. Br J Dermatol 1986; 114: 695-700.
55. 2006 - FDA Approves Updated Labeling with Boxed Warning and Medication Guide for Two Eczema Drugs, Elidel and Protopic [Internet]. [cited 2013 Nov 24]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ 2006/ucm108580.htm.
56. Taieb A, Legrain V, Palmier C, Lejean S, Six M, Maleville J. Topical ketoconazole for infantile seborrhoeic dermatitis. Dermatologica 1990; 181: 26-32.
57. Das J, Majumdar M, Chakraborty U, Majumdar V, Mazumdar G, Nath J. Oral itraconazole for the treatment of severe seborrhoeic dermatitis. Indian J Dermatol 2011; 56: 515-516.
58. Kose O, Erbil H, Gur AR. Oral itraconazole for the treatment of seborrhoeic dermatitis: an open, noncomparative trial. J Eur Acad Dermatol Venereol 2005; 19: 172-175.
59. Piérard-Franchimont C, Piérard GE, Arrese JE, De Doncker P. Effect of ketoconazole 1% and 2% shampoos on severe dandruff and seborrhoeic dermatitis: clinical, squamometric and mycological assessments. Dermatology 2001; 202: 171-176.
60. Faergemann J. Treatment of seborrheic dermatitis of the scalp with ketokonazole shampoo. A double-blind study. Acta Derm Venereol 1990; 70: 171-172.
61. Ratnavel RC, Squire RA, Boorman GC. Clinical efficacies of shampoos containing ciclopirox olamine (1.5%) and ketoconazole (2.0%) in the treatment of seborrhoeic dermatitis. J Dermatolog Treat 2007; 18: 88-96.
62. Squire RA, Goode K. A randomised, single-blind, singlecentre clinical trial to evaluate comparative clinical ef cacy of shampoos containing ciclopirox olamine (1.5 %) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff / seborrhoeic dermatitis. J Dermatol Treat 2002; 13: 51-60.
63. Danby FW, Maddin WS, Margesson LJ, Rosenthal D. A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff. J Am Acad Dermatol 1993; 29: 1008-1012.
64. Bailey P, Arrowsmith C, Darling K, Dexter J, Eklund J, Lane A, et al. A double-blind randomized vehicle-controlled clinical trial investigating the effect of ZnPTO dose on the scalp vs. antidandruff efficacy and antimycotic activity. Int J Cosmet Sci 2003; 25: 183-188.
65. Shin H, Kwon OS, Won CH, Kim BJ, Lee YW, Choe YB, et al. Clinical efficacies of topical agents for the treatment of seborrheic dermatitis of the scalp: a comparative study. J Dermatol 2009; 36: 131-137.
66. Faergemann J. Propylene glycol in the treatment of seborrheic dermatitis of the scalp: a double-blind study. Cutis 1988; 42: 69-71.
67. Emtestam L, Svensson Å, Rensfeldt K. Treatment of seborrhoeic dermatitis of the scalp with a topical solution of urea, lactic acid, and propylene glycol (K301): results of two double-blind, randomised, placebo-controlled studies. Mycoses 2012; 55: 393-403.
68. Papp KA, Papp A, Dahmer B, Clark CS. Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults. J Am Acad Dermatol 2012; 67: e11-e15.
69. Ang-Tiu CU, Meghrajani CF Maano CC. Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: a systematic review of randomized controlled trials. Expert Rev Clin Pharmacol 2012; 5: 91-97.
70. Shemer A, Kaplan B, Nathansohn N, Grunwald MH, Amichai B, Trau H. Treatment of moderate to severe facial seborrheic dermatitis with itraconazole: an open noncomparative study. Isr Med Assoc J 2008; 10: 417-418.
71. Akaza N, Akamatsu H, Sasaki Y, Kishi M, Mizutani H, Sano A, et al. Malassezia folliculitis is caused by cutaneous resident Malassezia species. Med Mycol 2009; 47: 618-624.
72. Bäck O, Faergemann J, Hörnqvist R. Pityrosporum folliculitis: a common disease of the young and middle-aged. J Am Acad Dermatol 1985; 12: 56-61.
73. Hay RJ. Superficial mycoses fungi and skin disease. London: Mosby-Wolfe. 1995. p. 113-151.
74. Levy A, Feuilhade de Chauvain M, Dubertret L, Morel P, Flageul B. Malassezia folliculitis: characteristics and therapeutic response in 26 patients. Ann Dermatol Venereol 2007; 134: 823-828.
75. Abdel-Razek M, Fadaly G, Abdel-Raheim M, al-Morsy F. Pityrosporum (Malassezia) folliculitis in Saudi Arabia - diagnosis and therapeutic trials. Clin Exc Dermatol 1995; 20: 406-409.
76. Jacinto-Jamora S, Tamesis J, Katigbak ML. Pityrosporum folliculitis in the Philippines: diagnosis, prevalence, and management. J Am Acad Dermatol 1991; 24: 693-696.
77. Yu HJ, Lee SK, Son SJ, Kim YS, Yang HY, Kim JH. Steroid acne vs. Pityrosporum folliculitis: the incidence of Pityrosporum ovale and the effect of antifungal drugs in steroid acne. Int J Dermatol 1998; 37: 772-777.
78. Parsad D, Saini R, Negi KS. Short-term treatment of Pityrosporum folliculitis: a double blind placebo-controlled study. J Eur Acad Dermatol Venereol 1998; 11: 188-190.
79. Rhie S, Turcios R, Buckley H, Suh B. Clinical features and treatment of Malassezia folliculitis with fluconazole in orthotopic heart transplant recipients. J Heart Lung Transplant 2000; 19: 215-219.
80. Ayers K, Sweeney SM, Wiss K. Diagnosis and management in 6 female adolescents with acne vulgaris. Arch Pediatr Adolesc Med 2005; 159: 64-67.
81. Friedman SJ. Pityrosporum folliculitis: treatment with isotretinoin. J Am Acad Dermatol 1987; 16: 632-633.
82. Svejgaard EL, Foged EK, Larsen PØ, Roed-petersen J, Petersen CS, Stenderup J, et al. [Guidelines for use of antimycotics in superficial mycoses.]. Ugeskr Laeger 2000; 2: 1-16 (in Danish).